Articles with public access mandates - De Lorenzo ClaudiaLearn more
Not available anywhere: 1
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab
V Quagliariello, M Passariello, C Coppola, D Rea, A Barbieri, M Scherillo, ...
International Journal of Cardiology 292, 171-179, 2019
Mandates: Government of Italy
Available somewhere: 26
Ranolazine protects from doxorubicin‐induced oxidative stress and cardiac dysfunction
CG Tocchetti, A Carpi, C Coppola, C Quintavalle, D Rea, M Campesan, ...
European journal of heart failure 16 (4), 358-366, 2014
Mandates: Government of Italy
Human anti-nucleolin recombinant immunoagent for cancer therapy
D Palmieri, T Richmond, C Piovan, T Sheetz, N Zanesi, F Troise, C James, ...
Proceedings of the National Academy of Sciences 112 (30), 9418-9423, 2015
Mandates: US National Institutes of Health
Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models
V Quagliariello, M Passariello, D Rea, A Barbieri, M Iovine, A Bonelli, ...
Journal of Personalized Medicine 10 (4), 179, 2020
Mandates: Government of Italy
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
S Camorani, M Passariello, L Agnello, S Esposito, F Collina, M Cantile, ...
Journal of Experimental & Clinical Cancer Research 39, 1-16, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production
G Riccio, S Antonucci, C Coppola, C D'Avino, G Piscopo, D Fiore, ...
Frontiers in physiology 9, 38, 2018
Mandates: US National Institutes of Health, Government of Italy
Long-chain polyphosphates impair SARS-CoV-2 infection and replication
V Ferrucci, DY Kong, F Asadzadeh, L Marrone, A Boccia, R Siciliano, ...
Science signaling 14 (690), eabe5040, 2021
Mandates: Government of Italy, AIRC Foundation for Cancer Research in Italy
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells
E Sasso, D Latino, G Froechlich, M Succoio, M Passariello, C De Lorenzo, ...
MAbs 10 (5), 730-737, 2018
Mandates: European Commission
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
C De Lorenzo, R Paciello, G Riccio, D Rea, A Barbieri, C Coppola, ...
OncoTargets and therapy, 2241-2250, 2018
Mandates: Government of Italy
A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor
G Riccio, C D'Avino, RT Raines, C De Lorenzo
Protein Engineering, Design & Selection 26 (3), 243-248, 2013
Mandates: US National Institutes of Health
Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
V Quagliariello, M Passariello, A Di Mauro, C Cipullo, A Paccone, ...
Frontiers in Cardiovascular Medicine 9, 930797, 2022
Mandates: Government of Italy
Ipilimumab and its derived EGFR aptamer-based conjugate induce efficient NK cell activation against cancer cells
M Passariello, S Camorani, C Vetrei, S Ricci, L Cerchia, C De Lorenzo
Cancers 12 (2), 331, 2020
Mandates: AIRC Foundation for Cancer Research in Italy
Interactions of spike-RBD of SARS-CoV-2 and platelet factor 4: new insights in the etiopathogenesis of thrombosis
M Passariello, C Vetrei, F Amato, C De Lorenzo
International Journal of Molecular Sciences 22 (16), 8562, 2021
Mandates: Government of Italy
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy
C D'Avino, D Palmieri, A Braddom, N Zanesi, C James, S Cole, ...
Oncotarget 7 (52), 87016, 2016
Mandates: US National Institutes of Health
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells
C D'Avino, R Paciello, G Riccio, M Coppola, P Laccetti, N Maurea, ...
Protein Engineering, Design & Selection 27 (3), 83-88, 2014
Mandates: US National Institutes of Health
High-throughput monoclonal antibody discovery from phage libraries: challenging the current preclinical pipeline to keep the pace with the increasing mAb demand
N Zambrano, G Froechlich, D Lazarevic, M Passariello, A Nicosia, ...
Cancers 14 (5), 1325, 2022
Mandates: Government of Italy
Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb
R Paciello, RA Urbanowicz, G Riccio, E Sasso, CP McClure, N Zambrano, ...
Journal of General Virology 97 (1), 82-94, 2016
Mandates: UK Medical Research Council
Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation
K Lacek, RA Urbanowicz, F Troise, C De Lorenzo, V Severino, A Di Maro, ...
Journal of Biological Chemistry 289 (50), 35015-35028, 2014
Mandates: UK Medical Research Council
Isolation of two novel human anti-CTLA-4 mAbs with intriguing biological properties on tumor and NK cells
M Passariello, C Vetrei, E Sasso, G Froechlich, C Gentile, AM D’Alise, ...
Cancers 12 (8), 2204, 2020
Mandates: Government of Italy
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
M Passariello, C Gentile, V Ferrucci, E Sasso, C Vetrei, G Fusco, ...
Scientific Reports 11 (1), 11046, 2021
Mandates: Government of Italy
Publication and funding information is determined automatically by a computer program